Mountain Valley MD Holdings Inc (CSE:MVMD, OTCQB:MVMDF) said it has appointed Dr Elizabeth Norton to an advisory position to support the company's key Quicksome vaccine and cold chain projects.
Norton is an immunologist with 20 years of experience in evaluating immunity, vaccines, and microbial infections. She has a public health and research background with a current faculty appointment as an associate professor with tenure in the Department of Microbiology & Immunology at Tulane University in Louisiana, in the United States.
"It is such an honor to be working with Norton on our advanced Quicksome vaccine applications," said Azhar Rana, chief medical officer at Mountain Valley MD. "Dr Norton's skill and expertise will be instrumental as we look at applying our Quicksome technology across an expanded variety of human and animal health vaccines with the goal of improving global vaccine access and effectiveness."
READ: Mountain Valley MD Holdings completes licensing agreement with Red White and Bloom Brands
Norton began her training at the Centers for Disease Control (CDC) and received an Master of Public Health in international health. In her doctoral and post-doctoral programs at Tulane University, she evaluated innate immunomodulation and mucosal delivery techniques, with the main focus of her lab to evaluate strategies to improve memory responses to vaccines through mucosal adjuvants.
Her work has involved the management of large, collaborative projects for adjuvanted polio and tuberculosis vaccines, and has also pioneered a derivative adjuvant for intranasal use in pneumonia, opioid, and influenza vaccines.
Since the pandemic, Norton also runs a project for the Tulane University Convalescent Antibody and Immunity Network (TUCAIN) National Institutes of Health /National Cancer Institute U54 evaluating cellular and memory responses to SARS-CoV-2 infection or vaccine responses in adults, children, and cancer subjects and oversees blood and tissue collections.
Norton has been consistently NIH-funded since 2013, authored over 30 peer-reviewed publications, received 3 patents, served on numerous NIH and other study sections and is a national and international speaker in her field.
Norton will be assuming the advisory responsibilities of Dr John D Clements, who is formally retiring from his advisory role within MVMD. Clements will continue to provide support on an ad-hoc basis to the company.
Contact Ritika at ritika@proactiveinvestors.com